Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1681/ASN.2014090859 http://scihub22266oqcxt.onion/10.1681/ASN.2014090859 C4625676!4625676!25858967     free     free     free Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Am+Soc+Nephrol 2015 ; 26 (11): 2741-52 Nephropedia Template TP {{tp|p=25858967|t=2015. A Podocyte-Based Automated Screening Assay Identifies Protective Small Molecules |pdf=|usr=}}{{25858967}} gab.com Text A Podocyte-Based Automated Screening Assay Identifies Protective Small Molecules JO: J Am Soc Nephrol http://www.kidney.de/pget.php?&tw=1&pmid=25858967 #FOAvip Podocyte injury and loss mark an early step in the pathogenesis of various glomerular diseases, making these cells excellent targets for therapeutics. However, cell?based high?throughput screening assays for the rational development of podocyte-directed therapeutics are currently lacking. Here, we describe a novel high?content screening?based phenotypic assay that analyzes thousands of podocytes per assay condition in 96-well plates to quantitatively measure dose-dependent changes in multiple cellular features. Our assay consistently produced a Z? value >0.44, making it suitable for compound screening. On screening with >2100 pharmacologically active agents, we identified 24 small molecules that protected podocytes against injury in vitro (1% hit rate). Among the identified hits, we confirmed an ?1-integrin agonist, pyrintegrin, as a podocyte-protective agent. Treatment with pyrintegrin prevented damage-induced decreases in F-actin stress fibers, focal adhesions, and active ?1-integrin levels in cultured cells. In vivo, administration of pyrintegrin protected mice from LPS?induced podocyte foot process effacement and proteinuria. Analysis of the murine glomeruli showed that LPS administration reduced the levels of active ?1 integrin in the podocytes, which was prevented by cotreatment with pyrintegrin. In rats, pyrintegrin reduced peak proteinuria caused by puromycin aminonucleoside?induced nephropathy. Our findings identify pyrintegrin as a potential therapeutic candidate and show the use of podocyte?based screening assays for identifying novel therapeutics for proteinuric kidney diseases. Twit Text FOAVip A Podocyte-Based Automated Screening Assay Identifies Protective Small Molecules ????J Am Soc Nephrol http://www.kidney.de/pget.php?&tw=1&pmid=25858967 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25858967 #FOAvip English Wikipedia <ref>{{Cite pmid|25858967}}</ref> A Podocyte-Based Automated Screening Assay Identifies Protective Small Molecules #MMPMID25858967 Lee HW; Khan SQ; Faridi MH; Wei C; Tardi NJ; Altintas MM; Elshabrawy HA; Mangos S; Quick KL; Sever S; Reiser J; Gupta V J Am Soc Nephrol 2015[Nov]; 26 (11): 2741-52 PMID25858967show ga Podocyte injury and loss mark an early step in the pathogenesis of various glomerular diseases, making these cells excellent targets for therapeutics. However, cell?based high?throughput screening assays for the rational development of podocyte-directed therapeutics are currently lacking. Here, we describe a novel high?content screening?based phenotypic assay that analyzes thousands of podocytes per assay condition in 96-well plates to quantitatively measure dose-dependent changes in multiple cellular features. Our assay consistently produced a Z? value >0.44, making it suitable for compound screening. On screening with >2100 pharmacologically active agents, we identified 24 small molecules that protected podocytes against injury in vitro (1% hit rate). Among the identified hits, we confirmed an ?1-integrin agonist, pyrintegrin, as a podocyte-protective agent. Treatment with pyrintegrin prevented damage-induced decreases in F-actin stress fibers, focal adhesions, and active ?1-integrin levels in cultured cells. In vivo, administration of pyrintegrin protected mice from LPS?induced podocyte foot process effacement and proteinuria. Analysis of the murine glomeruli showed that LPS administration reduced the levels of active ?1 integrin in the podocytes, which was prevented by cotreatment with pyrintegrin. In rats, pyrintegrin reduced peak proteinuria caused by puromycin aminonucleoside?induced nephropathy. Our findings identify pyrintegrin as a potential therapeutic candidate and show the use of podocyte?based screening assays for identifying novel therapeutics for proteinuric kidney diseases. äA Podocyte-Based Automated Screening Assay Identifies Protective Small(epmc).pdf DeepDyve Pubget Overpricing